The Case for Stratified Cost-Effectiveness Analysis by Baseline Health-Related QOL: Theory and Sensitivity Analysis

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.23, Iss.2, 2005-01, pp. : 121-132

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Valuing Health States for Use in Cost-Effectiveness Analysis

By Brazier John

PharmacoEconomics, Vol. 26, Iss. 9, 2008-01 ,pp. : 769-779

Adis International

Access to resources Recommend Favorite

The Importance of Cost Inputs and Sensitivity Analyses in a Cost-Effectiveness Analysis

By PharmD Jenna L. Yoder

Clinical Drug Investigation, Vol. 28, Iss. 7, 2008-01 ,pp. : 461-462

Adis International

Access to resources Recommend Favorite

Cost–effectiveness analysis in pharmacogenomics

By Payne Katherine Shabaruddin Fatiha H

Pharmacogenomics, Vol. 11, Iss. 5, 2010-05 ,pp. : 643-646

Future Medicine

Access to resources Recommend Favorite

Sensitivity Analysis in Cost-Effectiveness Studies: From Guidelines to Practice

By Jain Rahul

PharmacoEconomics, Vol. 29, Iss. 4, 2011-04 ,pp. : 297-314

Adis International

Access to resources Recommend Favorite

Health Utilities in Alzheimers Disease and Implications for Cost-Effectiveness Analysis

By Neumann Peter J.

PharmacoEconomics, Vol. 23, Iss. 6, 2005-01 ,pp. : 537-541

Adis International

Access to resources Recommend Favorite